Galderma Presents Phase 3 Relfydess Data and Dysport Innovations at TOXINS 2026

At the TOXINS 2026 International Conference in Madrid, Spain, earlier this month, Galderma shared a series of clinical and scientific updates on their portfolio of injectable aesthetics, including Relfydess (relabotulinumtoxinA) and Dysport (abobotulinumtoxinA).¹

A central focus of Galderma’s presence at TOXINS 2026 was Relfydess, the first and only ready-to-use liquid neuromodulator formulated with proprietary PEARL Technology. Unlike lyophilized botulinum toxin products requiring reconstitution, Relfydess is designed to preserve molecular integrity and deliver consistent dosing without preparation. Galderma presented data from 5 abstracts, including encore post-hoc subgroup analyses derived from pooled phase 3 READY program studies evaluating Relfydess in moderate to severe glabellar lines and lateral canthal lines.

Clinical Efficacy and Sustained Results

These analyses demonstrated high responder rates following treatment. More than 98% of patients treated for glabellar lines and over 88% treated for crow’s feet were assessed by investigators as responders at 1-month post-treatment. Importantly, both patients and investigators reported a median time of 24 weeks before return to baseline wrinkle severity for both facial indications, supporting sustained efficacy through about 6 months. The durability of effect was observed regardless of prior neuromodulator exposure, suggesting consistent performance across treatment-naïve and previously treated populations.²

“The READY phase 3 analyses presented at TOXINS 2026 reinforce Relfydess as a high-performance neuromodulator designed for fast onset, sustained results that last, and ease of use. The clinical studies show improvements in both frown lines and crow’s feet, as early as day one, as well as duration for 6 months, with up to 75% of patients not returning to baseline, aligning closely with the evolving expectations in aesthetic medicine. When combined with its unique PEARL Technology and ready to use liquid formulation, which is optimised for simple volumetric dosing and eliminates reconstitution variability for a more streamlined treatment approach, the data indicate that Relfydess meets the real-world needs of both practitioners and patients,” Sachin M. Shridharani, MD, FACS, board-certified plastic surgeon, founder of Luxurgery in New York, New York, and a associate clinical professor in the Division of Plastic and Reconstructive Surgery at Washington University School of Medicine in St Louis, Missouri, told Dermatology Times.

Safety, Diffusion, and Molecule Integrity

Additional new data included results from an in vivo head-to-head diffusion study comparing Relfydess with onabotulinumtoxinA in a rat model.³ The findings showed similar and limited diffusion profiles between the 2 agents, addressing an important safety and precision consideration in neuromodulator use. Collectively, the data further supports Relfydess’ rapid onset, long duration of effect, favorable safety profile, and high levels of patient satisfaction, as well as improvements in patient-reported well-being. The brand also hosted a dedicated Relfydess Masterclass, led by Joanna Czuwara, MD, PhD, and Birgit Blessmann-Gurk, MD.

“The TOXINS 2026 congress is an important forum to showcase the scientific progress shaping the future of neuromodulation, and Relfydess reflects Galderma’s leadership in that evolution. Through our proprietary PEARL Technology, we’ve introduced a novel approach designed to preserve molecule integrity to deliver fast and sustained results and expand what is scientifically possible in a ready-to-use liquid formulation. As we continue to grow our global neuromodulator portfolio, innovations like Relfydess underscore our commitment to advancing the category and supporting practitioners with next-generation aesthetic solutions,” Bill Andriopoulos, PhD, Head of Global Medical Affairs at Galderma, said to Dermatology Times.

In parallel, Galderma presented data on Dysport, one of the most widely used neuromodulators globally. The abstracts focused on patient and practitioner satisfaction following treatment of frown lines, including findings from a real-world study conducted in China.⁴ This study evaluated repeated Dysport treatment cycles and reported patient satisfaction rates reaching up to 100% 3 weeks after the third treatment cycle.

Galderma’s Future in Injectable Aesthetics

Overall, the presentations at TOXINS 2026 highlight the depth of Galderma’s neuromodulator portfolio and emphasize the efficacy of Relfydess and Dysport, particularly in meeting the needs of diverse, real-world populations.

“Today, Galderma is well positioned to be the leader in all aspects of Injectable Aesthetics, having the in-house capabilities to discover, research, develop, manufacture, and market best-in-class products,” the brand said in a press release.¹

References

1. TOXINS 2026: Clinical updates on Galderma’s leading neuromodulator portfolio further reinforce its leadership in Injectable Aesthetics. News release. Galderma. Published January 14, 2026. Accessed January 23, 2026. https://www.galderma.com/news/toxins-2026-clinical-updates-galdermas-leading-neuromodulator-portfolio

2. Ablon G, et al. RelaBoNT-A Treatment of Glabellar Lines and Lateral Canthal Lines of Different Baseline Severity: Subgroup Analyses of Pooled Phase III Study Data. Abstract #0080 presented at TOXINS; January 14-17, 2026; Madrid, Spain.

3. Nicodèm E, et al. Similar and Limited In Vivo Diffusion for relaBoNT-A and onaBoNT-A. Abstract #0103 presented at TOXINS; January 14-17, 2026; Madrid, Spain.

4. Huang J, et al. Subject and Physician Satisfaction With Repeated AbobotulinumtoxinA Treatments of Glabellar Lines in Chinese Subjects: Results From a Real-World Study. Abstract #0075 presented at TOXINS; January 14-17, 2026; Madrid, Spain.